spacer
home > ebr > summer 2004 > performance comparison of 60-mer and 25-mer in situ synthesised oligonucleotide microarrays
PUBLICATIONS
European Biopharmaceutical Review

Performance Comparison of 60-mer and 25-mer In Situ Synthesised Oligonucleotide Microarrays

Studies have suggested that 60-mer probes are more sensitive than 25-mer probes in microarray experiments, due to the longer length available for hybridisation (1). 60-mers are also more tolerant of sequence mismatches, which results in simplified analysis of highly polymorphic regions through the use of longer probes. We followed two different experimental approaches to compare the performance of 25-mers and 60-mers.

In the initial experiments, we evaluated two different microarrays manufactured with in situ synthesis inkjet printing, one employing 25-mer probes and the other 60-mer probes for each yeast open reading frame. In the second series of experiments, we evaluated 25-mer and 60-mer probes representing 500 human genes on a custom array containing 22,525 features. The genes were selected for this microarray either because they were known to be cancer related or because they were observed as up or down regulated in colon cancer samples experiments performed with Agilent Human 1A microarrays in earlier studies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Stephanie Fulmer-Smentek, Senior R&D Research Scientist at Agilent Technologies Inc and Luis Lombardia, Research Associate at Centro Nacional de Investigaciones Oncologicas (CNIO)*

Stephanie Fulmer-Smentek earned her PhD in Human Genetics from Johns Hopkins University in 1997. She then undertook postdoctoral research at Stanford University in the Department of Genetics. Stephanie joined Agilent Technologies Inc in 2000, and is now a Senior R&D Research Scientist in the Bioresearch Solutions Unit.


Luis Lombardia earned his PhD from Universidade Da Coruсa in 1998. He then spent two years as a postdoctoral fellow in CEA (Commisariat а l'Йnergie Atomique, Paris, France). Since 2001, Luis has been a Research Associate in the Genomics Unit of the Centro Nacional de Investigaciones Oncolуgicas.

spacer
Stephanie Fulmer-Smentek
spacer
spacer
spacer
Luis Lombardia
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta develops SARS-COV-2 neutralising Affimer reagents with therapeutic potential for COVID-19

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway1.
More info >>

White Papers

Clinical Trial Labelling – More Than Just Labels

Faubel & Co. Nachfolger GmbH

Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement